Cargando…

Protective effect of gonadotropin-releasing hormone agonist against chemotherapy-induced ovarian dysfunction: A meta-analysis

The protective effects of gonadotropin-releasing hormone agonist (GnRHa) against ovarian chemotherapy induced-toxicity have not completely been demonstrated and the impact of chemotherapy on ovarian dysfunction remains unclear. The present meta-analysis aimed to evaluate the efficiency of GnRHa and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Fei, Zhu, Bin, Feng, Qingjing, Wu, Lili, Cui, Yuechong, Liu, Yumo, Wang, Yingqian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507318/ https://www.ncbi.nlm.nih.gov/pubmed/31186748 http://dx.doi.org/10.3892/ol.2019.10252

Ejemplares similares

Gonadotropin-releasing hormone agonists for ovarian protection during breast cancer chemotherapy: a systematic review and meta-analysis
por: Li, Zhen-Yu, et al.
Publicado: (2022)

Effect of Timing of Gonadotropin-Releasing Hormone Agonist Administration for Ovarian Protection in Patients with Breast Cancer
por: Shin, Jae Jun, et al.
Publicado: (2020)

Is gonadotropin-releasing hormone agonist usage really leading to thyroid dysfunction?
por: Yilmaz, Nafiye, et al.
Publicado: (2019)

Gonadotropin-releasing hormone agonist protects ovarian function in young patients with ovarian malignancy undergoing platinum-based chemotherapy: A prospective study
por: Xie, Ya, et al.
Publicado: (2022)

Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review
por: Poggio, Francesca, et al.
Publicado: (2019)

Gonadotropin releasing hormone agonists: Expanding vistas
por: Magon, Navneet
Publicado: (2011)

The feasibility and efficacy of gonadotropin-releasing hormone agonists for prevention of chemotherapy induced ovarian failure in patient with gynecological malignancies
por: Park, Chan-Yong, et al.
Publicado: (2014)

Thyroid Dysfunction Associated with Administration of the Long-Acting Gonadotropin-Releasing Hormone Agonist
por: Han, Eun Jin, et al.
Publicado: (2013)

Transient impact of paclitaxel on mouse fertility and protective effect of gonadotropin-releasing hormone agonist
por: Ma, Nieying, et al.
Publicado: (2020)

Prediction of Successful Ovarian Protection Using Gonadotropin-Releasing Hormone Agonists During Chemotherapy in Young Estrogen Receptor-Negative Breast Cancer Patients
por: Lee, Dong-Yun, et al.
Publicado: (2020)

Gonadotropin-releasing hormone agonists during chemotherapy for ovarian function and fertility preservation for patients with early-stage breast cancer
por: Abdel-Razeq, Hikmat
Publicado: (2019)

Gonadotropin-releasing hormone agonist-induced pituitary apoplexy
por: Keane, Fergus, et al.
Publicado: (2016)

Gonadotropin-Releasing Hormone Agonist Therapy and Obesity in Girls
por: Shiasi Arani, Kobra, et al.
Publicado: (2015)

Gonadotropin-Releasing Hormone Agonist Induced Pituitary Apoplexy
por: Yu, Xiaoling, et al.
Publicado: (2021)

Thyroid Dysfunction after Gonadotropin-Releasing Hormone Agonist Administration in Women with Thyroid Autoimmunity
por: Marin, Loris, et al.
Publicado: (2022)

A Case of Thromboembolism After Injection of Gonadotropin-releasing Hormone Agonist
por: Zhou, Feng, et al.
Publicado: (2016)

Ovarian protection and safety of gonadotropin-releasing hormone agonist after cervical cancer surgery: systematic review and meta-analysis
por: Yuan, Jialing, et al.
Publicado: (2022)

Long-acting gonadotropin-releasing hormone agonist trigger in fertility preservation cycles before chemotherapy
por: Massarotti, C., et al.
Publicado: (2023)

Agonist-induced internalization and downregulation of gonadotropin-releasing hormone receptors
por: Finch, Ann R., et al.
Publicado: (2009)

The role of gonadotropin-releasing hormone agonists in female fertility preservation
por: Lee, Jae Hoon, et al.
Publicado: (2021)

Ovarian Function and Fertility Preservation in Breast Cancer: Should Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal Patients Receiving Chemotherapy?
por: Lambertini, Matteo, et al.
Publicado: (2019)

Pretreatment with gonadotropin-releasing hormone antagonist protects against chemotherapy-induced testicular damage ‘in mice
por: Levi, Mattan, et al.
Publicado: (2022)

Effects of a Gonadotropin‐releasing Hormone Agonist on Rat Ovarian Adenocarcinoma Cell Lines in vitro and in vivo
por: Maruuchi, Tatsuhiro, et al.
Publicado: (1998)

Gonadotropin-releasing hormone agonist ovulation trigger—beyond OHSS prevention
por: Castillo, Juan Carlos, et al.
Publicado: (2020)

Pituitary Apoplexy Secondary to Gonadotropin-Releasing Hormone Agonist for Breast Cancer
por: Mastandrea, Katherine, et al.
Publicado: (2023)

Dual trigger with gonadotropin releasing hormone agonist and human chorionic gonadotropin significantly improves live birth rate for women with diminished ovarian reserve
por: Lin, Ming-Huei, et al.
Publicado: (2019)

Half-dose, long-acting gonadotropin-releasing hormone agonist (Diphereline) is comparable with daily injections of short-acting gonadotropin-releasing hormone agonist (Suprefact) in IVF/ICSI cycles
por: Tehraninejad, Ensieh Sh., et al.
Publicado: (2010)

A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer
por: Asakawa, Jumpei, et al.
Publicado: (2018)

Concurrent Gonadotropin-Releasing Hormone Agonist Administration with Chemotherapy Improves Neoadjuvant Chemotherapy Responses in Young Premenopausal Breast Cancer Patients
por: Kim, Hee Jeong, et al.
Publicado: (2015)

A Case of Ovarian Steroid Cell Tumor, Not Otherwise Specified, Treated with Surgery and Gonadotropin Releasing Hormone Agonist
por: Chung, Dong-Hae, et al.
Publicado: (2014)

Investigation of pregnancy outcome and ovarian hyper stimulation syndrome prevention in agonist and antagonist gonadotropin-releasing hormone protocol
por: Rabati, Behnaz Khani, et al.
Publicado: (2012)

Functional Ovarian Cysts in Artificial Frozen-Thawed Embryo Transfer Cycles With Depot Gonadotropin-Releasing Hormone Agonist
por: Ji, Hui, et al.
Publicado: (2022)

Gonadotropin-releasing hormone agonist for the preservation of ovarian function in survivors of haematopoietic stem cell transplantation for haematological diseases
por: Wang, Zhenhong, et al.
Publicado: (2022)

Reproductive responses of dairy cows with ovarian cysts to simultaneous human chorionic gonadotropin or gonadotropin-releasing hormone and cloprostenol compared to gonadotropin-releasing hormone alone treatment
por: Taktaz, T., et al.
Publicado: (2015)

A randomized controlled trial of gonadotropin-releasing hormone agonist versus gonadotropin-releasing hormone antagonist in Iranian infertile couples: oocyte gene expression
por: Hoseini, Fatemeh Sadat, et al.
Publicado: (2014)

Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Has the Same Effect as Gonadotropin-Releasing Hormone Agonist Injections in Terms of Preparation for Transcervical Resection Myomectomy
por: Ito, Mika, et al.
Publicado: (2022)

Utility of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a systematic review and meta-analysis
por: Shen, Yan-Wei, et al.
Publicado: (2015)

Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer
por: Gründker, Carsten, et al.
Publicado: (2003)

Role of Gonadotropin-Releasing Hormone (GnRH) in Ovarian Cancer
por: Gründker, Carsten, et al.
Publicado: (2021)

Gonadotropin releasing hormone analogs as part of controlled ovarian stimulation
por: Fleming, Richard
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jld5328vlh2k7gmpqt9qfi35ud